We examined the epidemiology of HCC and other liver events in a multi-cohort collaboration of HIV/HCV co-infected individuals. We observed shifts in incidence from 2001 to 2014 and identified age, cirrhosis, and low current CD4 cell count as risk factors.
TEXT BACKGROUND
As hepatitis C virus (HCV) and human immunodeficiency virus (HIV) have shared modes of transmission, individuals with HIV are more often infected with HCV than the general population [1] . HCV can cause chronic hepatic inflammation leading to liver fibrosis and cirrhosis that entails a risk of liver decompensation and hepatocellular carcinoma (HCC) [2] . Concomitant HIV infection accelerates this process [3, 4] . It is therefore not surprising that liver disease is one of the main causes of death in people with HIV [5] . Some studies indicate that the overall rate of liverrelated death is declining in HIV/HCV co-infected individuals [6] , but at the same time, national cohort studies have shown an increasing rate of HCC [7] [8] [9] .
We aimed to study HIV/HCV co-infected individuals in Europe and Canada and describe trends in the incidence of HCC and other liver events from 2001 to 2014 and identify risk factors for the development of HCC and other liver events.
METHODS

Study population
We included all HIV/HCV co-infected individuals in four prospective cohorts of HIVpositive individuals: the EuroSIDA study [10] , which enrolls HIV-positive individuals from 107 clinics across Europe, Israel, and Argentina; the Southern Alberta Clinic Cohort [11] , which enrolls individuals receiving HIV care in Southern Alberta, Canada; the Canadian Co-infection Cohort study (CTN222) [12] , which enrolls HCV co-infected HIV-positive individuals from 18 centers across Canada; and the Swiss HIV Cohort Study [13] , which enrolls HIV-positive individuals from Switzerland.
All cohorts collect and update data at least every six months using standardized collection forms.
We defined HCV co-infection as being HCV antibody-positive. Baseline was defined as the latest of first cohort or clinic visit; first positive HCV antibody-test; or January 1, 2001 (since data on non-AIDS defining cancers, including HCC, were collected prospectively from this date).
Data from all participating cohorts were pooled together by use of the HIV Cohort Data Exchange Protocol [14] , which is freely available at www.hicdep.org.
Outcomes
We studied two separate outcomes: 1) HCC, and 2) other liver events, defined as liver decompensation or liver-related death. Liver decompensation was defined as hepatic encephalopathy (grade 3 or 4), hepatorenal syndrome, ascites, variceal bleeding, or spontaneous bacterial peritonitis.
Liver-related death was defined as deaths caused by chronic viral hepatitis or other liver failure, excluding HCC. The diagnoses were based on pathology reports, hospital discharge summaries, or consultation notes from the hospitalization or clinic. For HCC, in the absence of the above, the diagnosis could also be based on a strong suspicion supported by evidence from radiological imaging or biochemical assay. All events were subsequently centrally reviewed.
Statistical analysis
Crude incidence rates of both HCC and other liver events were calculated by calendar time, grouped into two-year periods, and stratified by latest cirrhosis status and CD4 cell count, also testing for interaction between cirrhosis status and current CD4 cell count.
Poisson generalized estimating equations assuming auto-regressive (AR1) correlation were used to investigate the association between various demographic, HIV, and lifestyle related characteristics and the incidence of HCC and other liver related events, separately. Variables significant in the univariate regression models (P<0.1) were included in the multivariate regression models.
Sensitivity analyses were performed which excluded HCC cases with HIV/HCV/HBV co-infection or those with any cancer diagnosis (other than HCC) prior to end of follow-up.
All statistical tests were two sided with a type I error rate of 5%. Statistical analyses were performed using SAS 9.3 (Statistical Analysis Software, Cary NC, USA).
Predictor variables
The following variables were considered for inclusion in the regression models: age, sex*, race* (white, other/unknown), region* (Europe East/Argentina, Europe West, Canada), HIV risk group* (men who have sex with men (MSM), injection drug use (IDU), heterosexual, other/unknown), body mass index (BMI) category, ever smoked, ever abused alcohol, diabetes mellitus, Diabetes mellitus was defined as having a diagnosis of insulin-dependent diabetes mellitus or taking diabetic medication or insulin. HBV co-infection was defined as the presence of hepatitis B surface antigen in serum. cART was defined as receiving at least three antiretrovirals from any class. Detectable HIV RNA was defined as having plasma HIV RNA above 400 copies per milliliter.
Cirrhosis was defined using a hierarchical structure using cutoffs from earlier publications [15] [16] [17] : A liver biopsy with a METAVIR score of F4 was considered the highest level of evidence, followed by a FibroScan elasticity of 12.5 kPa or above, then an aspartate aminotransferase-toplatelet ratio index (APRI) of 2 or above, and then a plasma hyaluronic acid level of 200 ng/ml or above. The individual patient was assumed cirrhotic from the date of measurement and onwards if the measurement fulfilled at least one of the criteria mentioned above. If different markers were incon-sistent, the marker of highest evidence level decided the cirrhosis status. Individuals in whom we could not assess cirrhosis status were classified as "missing".
RESULTS
Baseline characteristics
We included 7,229 individuals in our study (4,132 from the EuroSIDA Study; 2,044 from the Swiss HIV Cohort Study; 840 from the Canadian Co-infection Cohort; 213 from the Southern Alberta Clinic Cohort). Table 1 shows the baseline characteristics of our study population. The majority were male (68%), white (90%), and primarily from Europe West (58%). Median age was 38 (inter-quartile range (IQR): 36, 43) years. The main HIV risk group was IDU (59%), and 5% were HIV/HCV/HBV co-infected. In individuals with cirrhosis, the overall incidence rate of HCC was 7.9 (95% CI: 5.9, 10.5) cases per 1,000 person-years of follow-up against 0.5 (95% CI: 0.3, 0.7) cases per 1,000 personyears of follow-up in individuals who did not have cirrhosis according to our definition. For other liver events, the incidence rates were 35.9 (95% CI: 31.1, 41.4) and 2.4 (95% CI: 1.9, 3.0) cases per 1,000 person-years of follow-up in cirrhotics and non-cirrhotics, respectively.
Incidence rates of HCC and other liver events
When further stratifying for current CD4 cell count, we found that the incidence rates of both outcomes were lower in those with a current CD4 cell count above 350 cells/mm 3 in both those with and without cirrhosis ( Figure 2 ). For individuals with cirrhosis, the incidence rate of HCC decreased from 10.9 (95% CI: 7.4, 16,1) cases per 1,000 person-years of follow-up in those with a CD4 cell count below 350 cells/mm 3 to 6.1 (95% CI: 3.8, 9.7) cases per 1,000 person-years of followup in those with a CD4 cell count above 350 cells/mm 3 . For other liver events, the effect of current CD4 cell count was more drastic, as the incidence rate here went from 58.7 (95% CI: 49.2, 70.0) to 20.1 (95% CI: 15.5, 26.4) cases per 1,000 person-years of follow-up, respectively. Formal statistical interaction analyses did not identify a significant interaction between cirrhosis and current CD4 cell count for any outcome (both p > 0.2), but the analyses had low power. Table 2 shows the characteristics at event in those who developed HCC or other liver events and at end-of-follow-up in the remaining cohort. Median age at event was 49.6 years for HCC versus 43.9 years for other liver events. Within two years of event, 75% of those who developed HCC and 70% of those who developed other liver events had cirrhosis. Only 8% of HCC cases and 6% of other liver events cases were HBV co-infected. 32% of those who developed HCC had ever taken HCV active drugs versus 18% of those who developed other liver events. Almost all had ever taken cART (99% of HCC cases and 91% of other liver events cases), but their most recent (within six months) CD4 cell counts were however still quite low with a median of 286 (IQR: 201, 438) cells/mm 3 for those who developed HCC and 242 (IQR: 110, 397) cells/mm 3 for those who developed another liver event.
Characteristics at event
Of the 11 of those who developed HCC that had an HCV RNA measurement at least six months after completing interferon-based treatment, none had achieved a sustained virologic response (SVR).
Risk factors for HCC and other liver events
In multivariate analysis of HCC (Table 3) , higher age, HBV co-infection, lower current CD4 cell count, and cirrhosis were associated with a higher incidence of HCC. Notably, we found no impact of alcohol abuse, diabetes mellitus, or detectable HIV RNA on the incidence of HCC in univariate analysis.
Later calendar years were significantly associated with a higher incidence of HCC events in univariate analysis, but not in multivariate analysis, indicating that changes in some of the other variables explained the increase over time. In a supplementary analysis, increases in the proportion with cirrhosis mostly explained the increase in HCC over time, as it was only after adjustment for cirrhosis that there no longer was a significant increase in HCC over time (adjusted incidence rate ratio per calendar year increase 1.05, 95% CI: 0.98, 1.13).
The multivariate analysis of other liver events yielded similar risk factors (Figure 3 and Supplementary Table 1 ): higher age, lower CD4 cell count, and cirrhosis (but not HBV co-infection) were associated with a higher incidence of other liver events. However, the HIV risk group "other/unknown" compared with MSM, being underweight, and having ever smoked were also significant risk factors for other liver events. The decrease in other liver events per calendar year in the univariate analysis did remain significant in multivariate analysis.
Excluding those with HBV co-infection or those with any other cancer diagnosis prior to end-of-follow-up did not change the results (data not shown).
DISCUSSION
We observed opposing trends in the incidence of HCC and other liver events in HIV/HCV co-infected individuals from 2001 to 2014: HCC increased from 0.4 to 2.3 cases per 1,000 person-years of follow-up, whereas other liver events decreased from 9.9 to 5.2 cases per 1,000 person-years of follow-up.
The increase in HCC incidence has previously been shown in national and mostly retrospective studies of HIV/HCV co-infected individuals: in Spain, Merchante et al. [8] showed that the incidence increased from 2000 to 2010 (0.2 to 1.4 cases per 1,000 person-years of follow-up), and, in a study of the Veterans Affairs Cohort in the United States, Ioannou et al. [9] found that the ageadjusted prevalence of HCC increased from 0.15% in 1996 to 1.06% in 2009. The authors of these studies point to the increased survival in individuals with HIV as an explanation for the rise in incidence, as HCV-related development of cirrhosis and subsequent HCC takes several years [18] . Our results support this reasoning as changes in the proportion of individuals with cirrhosiswhich we found to increase by 8% per year in a post-hoc analysis (data not shown)mostly explained the increase in HCC per calendar year in multivariate analysis.
However, while the proportion of cirrhotics and incidence of HCC was increasing, we found that the incidence of other liver events, i.e. liver decompensations and liver-related deaths, decreased. Other recent studies of HIV/HCV co-infected individuals, but not all [19] , have shown similar trends [5] [6] [7] 20] . This could potentially be explained by the increased uptake of cART, which has been found to lower the progression of hepatic fibrosis and disease [21, 22] , improved HCV treatment uptake [23] , and possibly the switch from older hepatotoxic antiretrovirals such as zidovudine, didanosine, and stavudine to newer drugs [24] . In our analysis, prior cART and and prior HCV active drug treatment did not impact on the decrease of other liver events per calendar year in multivariate analysis, but an increase of CD4 cell count did protect against the development of other liver events, and the population as a whole had higher CD4 cell counts at end-of-follow-up. Improvements in HIV and HCV treatment have undoubtedly reduced the risk of liver decompensations or liver-related death in the last decade, but our data suggest that other explanatory factors are yet to be accounted for.
Thus, taken together, our study has shown opposing shifts in the incidence of HCC and other liver events. It seems paradoxical that improvements in liver-related morbidity in HIV/HCV coinfected patients, demonstrated by a lower incidence of other liver events, would at the same time yield a higher incidence of HCC. One explanation could be that an improved management of liver cirrhosis and HIV treatment can increase the threshold for liver decompensation in the cirrhotic HIV/HCV co-infected individuals, but thus increasing longevity to a point where viral hepatocarcinogenesis has had enough time to manifest itself as HCC. This hypothesis is somewhat supported in our finding that for cirrhotics, the decrease in incidence rate was much more pronounced for other liver events than for HCC when comparing those with a current CD4 cell count less than 350 cells/mm 3 to those with a count above 350 cells/mm 3 , though formal analysis for interaction between cirrhosis and current CD4 cell count was not statistically significant.
In our multivariate analysis, the major risk factor for HCC was cirrhosis. We found that 74% of individuals with HCC had cirrhosis within six months of HCC diagnosis. As "missing" cirrhosis status also was associated with a higher incidence of HCC, it is likely that the markers used in our definition of cirrhosis have not identified all true cirrhotics, rather than an actual situation in which 26% of individuals developed HCC without cirrhosis. However, as liver biopsies are being continuously replaced by the same non-invasive markers, our results warns that HCC can develop in individuals who do not seem to have cirrhosis based on these markers.
We also found that lower current CD4 cell count was associated with HCC in HIV/HCV co-infected individuals. Previous studies have also shown this in HIV individuals in general [9, 25, 26] , but in HCV/HIV co-infected individuals, the results have been conflicting: Salmon et al. [27] did not find an association, arguing that any association is likely confounded by cirrhosis as concomitant splenic sequestration of lymphocytes artificially lowers the CD4 cell count [28] . But in a more recent study, Kramer et al. [29] found that having a CD4 cell count of <200 cells/mm 3 (compared with >350 cells/mm 3 ) was associated with a 1.7 times greater hazard of HCC, and the association remained when analyzing a subgroup with cirrhosis. In our studywhere we treated CD4 cell count as a continuous variablewe found a statistically significant protective effect of a doubling in current CD4 cell count after adjustment for cirrhosis, corroborating the independent effect of current immunosuppression as a risk factor of HCC.
In addition to cirrhosis and CD4 cell count, HBV co-infection and higher age were significant risk factors for HCC. All these are clinically relevant parameters that can help the treating physician assess each HIV/HCV co-infected individual's risk of liver malignancy. However, the risk factors we identified for HCC were also independent risk factors for other liver events (except for HBV co-infection). The effect sizes were different, but for a singular case, the clinician should perceive the aforementioned risk factors as more general predictors of liver disease and death, and not HCC exclusively, especially as the incidence of HCC, though increasing, remains low.
Our study has several limitations: First, our diagnosis of cirrhosis was based primarily on non-invasive techniques. However, the measurements and their respective cutoffs have been validated [30] , and possible misclassifications would underestimate any real effect of cirrhosis in our analyses, where it in fact was the strongest predictor. Second, we defined (chronic) HCV co-infection by the presence of HCV antibodies, and as around 20% can clear the infection spontaneously, we might have included some individuals with resolved HCV infection. Third, data on alcohol abuse were only recently added to some of our cohorts and thus very limited. The major strength of our study is that our population is taken from prospective cohorts, representing a large portion of Europe and Canada and with a relatively large proportion of females rendering our results readily applicable to the Caucasian population.
In conclusion, we observed that from 2001 to 2014, the incidence of HCC in HIV/HCV co-infected individuals increasedlargely explained by an increase in the number of individuals with cirrhosiswhereas the rate of other liver events (liver decompensations and liver-related deaths) decreased. Higher age, cirrhosis, and lower current CD4 cell counts were independent risk factors for both HCC and other liver events. New treatment of HCV with direct acting antivirals and earlier HIV treatment will likely reduce the rates of HCC and other liver events, but as HCC still can develop after achieving SVR [31] , or as a consequence of long-tern alcohol abuse, non-alcoholic steatohepatitis or other hepatotoxic exposures, continuous surveillance of incidence trends is needed. a Variables with a p-value of < 0.10 in the univariate analysis were included in the multivariate analysis. 
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